Insight Molecular Diagnostics Inc. — Director's Dealing 2020

Dec 23, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2020-12-21

Reporting Person: KINGSLEY ALFRED D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-21	Common Stock, no par value	M	47976	$1.34	Acquired	350787	Direct
2020-12-21	Common Stock, no par value	S	30000	—	Disposed	320787	Direct
2020-12-21	Common Stock, no par value	S	5148	$2.54	Disposed	315639	Direct
2020-12-22	Common Stock, no par value	M	10516	$1.34	Acquired	326155	Direct
2020-12-22	Common Stock, no par value	S	7652	—	Disposed	318503	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-21	Option to purchase common stock	$1.34	M	47976	Acquired	2020-12-28	Common Stock (47976)	Direct
2020-12-22	Option to purchase common stock	$1.34	M	10516	Acquired	2020-12-28	Common Stock (10516)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	75345	Indirect
Common Stock, no par value	18767	Indirect

Footnotes

F1: Shares sold at price ranging from $2.50 - $2.54.

F2: Shares sold at price ranging from $2.54 - $2.55.

F3: The shares of common stock are held by Greenbelt Corp. The Reporting Person is the President of Greenbelt Corp. and in such capacity has the right to vote and dispose of the securities held by such entity.

F4: The shares of common stock are held by Greenway Partners, LP. The Reporting Person is the General Partner of Greenway Partners, LP and in such capacity has the right to vote and dispose of the securities held by such entity.

F5: The options vested and became exercisable in equal quarterly installments on the last day of each calendar quarter over a four-year period from the date of grant on December 29, 2010.